C Cumberland Pharmaceuticals Inc
C
Închisă
5.46 13.04
Rezumat
Modificarea prețului
24h
Minim
4.71
Maxim
5.51
Venit | -1.9M -3.3M |
|---|---|
Vânzări | -4.5M 9.1M |
Marjă de profit | -35.998 |
Angajați | 93 |
EBITDA | -1.9M -1.9M |
Următoarele câștiguri | 4 aug. 2026 |
|---|
Capitalizare de piață | 719K 68M |
|---|---|
Deschiderea anterioară | -7.58 |
Închiderea anterioară | 5.46 |
Scor tehnic
By Trading Central
Încredere
Very Strong Bearish Evidence
Cumberland Pharmaceuticals Inc Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
Cumberland Pharmaceuticals Inc Așteptări
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Costul vânzărilor
Profit brut din vânzări
Cheltuieli cu dobânzile pe datorie
EBITDA
Profit operațional
$
Despre Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
